The global paints and coatings market is extremely fragmented due to the presence of numerous companies. The competition among the players is expected to intensify over the next couple of years wing to the low degree of product differentiation among the producers of paints and coatings. To cater to the unmet needs of end users, the companies have extensively increased their production capacity. To gain a strong position in the market, the manufacturers are focusing on product innovation and sustainability. Some of the leading players in the market are RPG International, The Valspar Corporation, BASF SE, Axalta Coatings, Sherwin-Williams Company, PPG Industries, and AkzoNobel N.V. In terms of geography, Asia Pacific emerged dominant with regards to consumption in 2012. The market for paints and coatings in the Asia Pacific region is further expected to grow over the coming years. Europe is expected to witness an accelerated sales owing to the mounting demand for paints and coatings in the automotive and aviation industry.
Market to Gain from Rising Demand from End Users
Construction Industry to Emerge as Prime Revenue Generator
Regions such as Europe and Asia Pacific have witnessed significant growth in their respective construction industries. The growing need to accommodate the rising population has boosted the construction of new residential and commercial buildings, in turn driving the demand for paints and coatings. However, stringent regulations to control the amount of volatile compound used may hamper the growth of the market. The global paints and coatings market is expected to steadily rise over the forecast period. The market is anticipated to gain momentum and reach a valuation of US$143.9 bn by the end of 2019.
» Renal Cluster Drug Development Pipeline Review, 2017
» Womens Health Cluster Drug Development Pipeline Review, 2017
» Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017
» CNS Cluster Addiction Drug Development Pipeline Review, 2017
» Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017